[autotag]Joilton Lutterbach[/autotag] will not make the walk to the octagon after all, as he’s been released from his UFC contract following a failed drug test that canceled his promotional debut.
Combat Sports Anti-Doping, which handles the UFC anti-doping program along with Drug Free Sport International, announced the news of Lutterbach’s release and acceptance of a 24-month suspension Tuesday.
Lutterbach (38-10) was supposed to make his UFC debut against Shara Magomedov in June. However, Lutterbach tested positive for the presence of 3a-Hydroxy-2a-methyl-5a-androstan-17-one, a metabolite of drostanolone, an anabolic steroid that is prohibited at all times. The failed test came from a urine sample collected by DFSI on June 8 after he signed a bout agreement in May.
Lutterbach admitted that he used performance-enhancing drugs prior to signing with the UFC, but only after his failed test. Athletes who sign with the UFC are required to declare any use of prohibited substances upon being added to the anti-doping program, and could be required to wait 180 days and provide at least two negative samples before they can be booked to fight. Lutterbach made no declaration of his drostanolone use in time and therefore was handed the two-year sanction and released.
Lutterbach, who fights out of Germany, competed across several combat sports. He’s currently on a three-fight winning streak in MMA, with his most recent loss coming against Clay Collard under the PFL banner in 2021. Lutterbach has competed for many notable MMA promotions such as the PFL, Brave, Cage Warriors, and ACB.
He’s competed three times in 2024, once in boxing and twice for Karate Kombat.
[lawrence-auto-related count=3 category=420030788]
